2 weeks Ago By ABMN Staff
Becton, Dickinson and Company ( NYSE:BDX – Get Free Report ) is set to announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of $3.77 per share for the quarter.
Parties interested in participating in the company’s conference call can do so using this link . Becton, Dickinson and Company Stock Performance BDX stock opened at $237.30 on Wednesday.
Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $259.92.
The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.
70. The company has a market cap of $68.59 billion, a P/E ratio of 48.
83, a price-to-earnings-growth ratio of 1.76 and a beta of 0.43.
The business’s fifty day moving average is $237.51 and its 200-day moving average is $235.12.
Wall Street Analyst Weigh In A number of equities analysts have issued reports on the company. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the stock from $255.00 to $275.
00 in a report on Tuesday, October 1st. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.
00 and gave the company a “buy” rating in a report on Friday, July 26th. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th.
Evercore ISI lifted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st.
Finally, Raymond James lowered their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd.
Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $282.63. Becton, Dickinson and Company Company Profile ( Get Free Report ) Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. Further Reading Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter .
.
